Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business
Clarivate (NYSE:CLVT) will sell its Life Sciences & Healthcare unit to Altaris for $600M to refocus on Academia & Government and Intellectual Property, according to company executives. Clarivate affirmed 2026 guidance midpoints except free cash flow, citing added transaction costs. Pro forma revenue and adjusted EBITDA would be down about $370M and $120M, but free cash flow is expected to hold.
How this was made
The 30-second read
Why it matters
The transaction is expected to raise recurring organic revenue mix, profit margin, and free cash flow margin while reducing capital spending and interest expense, but it also brings non-recurring transaction costs and discontinued-operations reporting starting in the second half.
Market read
Provides deal terms and quantified pro forma financial effects, enabling traders to reprice CLVT around FCF margin expansion and deal-close execution risk.
What to watch
The article notes additional transaction costs and discontinued-ops classification; traders should watch for any changes to closing timeline, working-capital adjustments, or customer cross-selling separation impacts.
Background
Clarivate plc is refocusing from three segments toward two core businesses after agreeing to divest its Life Sciences & Healthcare unit.
Ticker impact
Clarivate will sell its Life Sciences & Healthcare unit to Altaris for $600M and shift focus to Academia & Government and Intellectual Property.
Likely positive medium-term bias as investors model higher FCF margin and lower capex, with near-term volatility around deal-close and cost assumptions.
The article provides deal consideration ($600M), pro forma revenue/EBITDA impacts, specific margin and capex/FCF improvements, and non-recurring transaction costs, which are directly modelable for CLVT.
Market effects
Signals continued portfolio rationalization in information and analytics software, with investors favoring higher recurring revenue mix and lower capex intensity.
Limited direct regional read-through; primarily affects US-listed software/information services sentiment.
Deal economics and AI/go-to-market emphasis may influence global peers’ capital allocation narratives around non-core divestitures.
Counterpoint
Improved pro forma metrics may be partially offset by execution risk in separating businesses, customer retention, and timing of cost savings through closing.
Key entities
- companyClarivate plc
NYSE-listed information and analytics company selling its Life Sciences & Healthcare unit for $600M and refocusing on Academia & Government and Intellectual Property.
- buyerAltaris
The acquirer of Clarivate’s Life Sciences & Healthcare segment for $600M, per the article.
